Clinical Trial Update: Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC [Phase 2]

View source ↗

Summary

A phase 2 clinical trial update on a neo-adjuvant treatment with AZD9291 (osimertinib) for EGFR-mutant stage IIIA/B non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: Shaare Zedek Medical Center | Conditions: Lung Cancer, Non-small Cell | Phase 2 | Status: UNKNOWN